RDUS - Rasio utang marang kapitalisasi buku Radius Recycling Inc.

Logo grafis Radius Recycling Inc. (RDUS)

Metal recycling operations provide Radius Recycling, Inc. (RDUS) with sustainable working capital. The debt-to-capitalization ratio reflects current dynamics, where the parameter value equals 1.13. Its status as a key scrap aggregator guarantees stable demand, while developments in molecular biology and synthesis establish a robust scientific foundation for the company's future growth.

RDUS (Radius Pharmaceuticals) riwayat Utang marang nilai buku saka 04.07.2022 nganti 26.07.2025

Radius Recycling Inc. (RDUS) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Rega saham Radius Recycling, Inc.|RDUS - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar Radius Pharmaceuticals|RDUS - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Radius Recycling|RDUS - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku radiuspharm.com|RDUS - Total Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas Radius Recycling, Inc.|RDUS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Radius Health|RDUS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Radius Pharmaceuticals|RDUS - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Radius Recycling
Analisis fundamental perusahaan:Radius Recycling, Inc. - RDUS
Barang utama Radius Health

When assessing the resilience of Radius Recycling, Inc. (RDUS), I focus on the capital structure. This ratio compares total borrowings to the company's book value, measuring the degree of financial autonomy. By analyzing the dynamic debt-to-book capitalization metric, an investor determines the risk of credit pressure. For Radius Recycling, Inc. (RDUS), a low debt load confirms operational reliability, which reinforces B2B partner confidence in a stable metal recycling operator.

Pesaing Radius Recycling, Inc. (RDUS)

Utang-utang marang kapitalisasi buku ASND (Ascendis Pharma A/S)|madrigalpharma.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Corcept Therapeutics Incorporated (CORT)|RYTM: Rasio utang marang aset resik|AKRO (Akero Therapeutics Inc) - Rasio utang marang kapitalisasi buku|Metsera Therapeutics (MTSR) - Utang marang nilai buku|MLTX (MoonLake Immunotherapeutics) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Utang marang nilai buku|Rasio utang marang aset resik SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Rasio utang marang kapitalisasi buku|Utang marang nilai buku 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Utang-utang marang kapitalisasi buku|structuretx.com (GPCR) - Utang-utang marang nilai buku|MDXG - Utang marang nilai buku|Rezolute Inc (RZLT) - Utang marang modal buku|LXRX (Lexicon Pharma) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku MBX Corp|Utang-utang marang kapitalisasi buku Altimmune, Inc. (ALT)|Rasio utang marang kapitalisasi buku AARD (aardvarktherapeutics.com)|SGMT: Rasio utang marang kapitalisasi buku|BioAge Labs - Utang-utang marang nilai buku|BMEA - Rasio utang marang kapitalisasi buku|QNCX - Rasio utang marang kapitalisasi buku|Fractyl Health, Inc. - Utang-utang marang kapitalisasi buku|VTVT (vTv Therapeutics) - Utang-utang marang aset resik|ATPC: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik PLUR|Rasio utang marang kapitalisasi buku SYBX (Synlogic, Inc.)|Utang marang nilai buku LPCN (Lipocine Corporation)|Rasio utang marang kapitalisasi buku Matinas BioPharma Holdings|Rasio utang marang aset resik Spruce Biosciences Inc. SPRB|Galecto - Utang-utang marang kapitalisasi buku|CTCX - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Lumos Pharma Corp|Organovo Corp (ONVO) - Rasio utang marang nilai buku